Label: CYPROHEPTADINE syrup

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated July 31, 2013

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    Rx ONLY

  • DESCRIPTION

    Each 5 mL (one teaspoonful) contains: Cyproheptadine hydrochloride 2 mg. Alcohol 5%.

    Inactive ingredients: citric acid, D&C Yellow No.10, peppermint flavor, purified water, sodium benzoate, sodium citrate and sucrose.

    Cyproheptadine hydrochloride is an antihistaminic and antiserotonergic agent. Cyproheptadine hydrochloride is a white to slightly yellowish, crystalline solid, with a molecular weight of 350.88, which is slightly soluble in water, freely soluble in methanol, sparingly soluble in ethanol, soluble in chloroform and practically insoluble in ether. It is the sesquihydrate of 4-(5H-Dibenzo [a,d] cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride. The molecular formula of the anhydrous salt is C21H21N • HCl and the structural formula of the anhydrous salt is:

    Chemical Structure
  • CLINICAL PHARMACOLOGY

    Cyproheptadine is a serotonin and histamine antagonist with anticholinergic and sedative effects. Antiserotonin and antihistamine drugs appear to compete with serotonin and histamine, respectively, for receptor sites.

    Pharmacokinetics and Metabolism

    After a single 4 mg oral dose of 14C-labeled cyproheptadine HCl in normal subjects, given as tablets or oral solution, 2-20% of the radioactivity was excreted in the stools. Only about 34% of the stool radioactivity was unchanged drug, corresponding to less than 5.7% of the dose. At least 40% of the administered radioactivity was excreted in the urine. No detectable amounts of unchanged drug were present in the urine of patients on chronic 12-20 mg daily doses of cyproheptadine oral solution. The principal metabolite found in human urine has been identified as a quaternary ammonium glucuronide conjugate of cyproheptadine. Elimination is diminished in renal insufficiency.

  • INDICATIONS AND USAGE

    Perennial and seasonal allergic rhinitis

    Vasomotor rhinitis

    Allergic conjunctivitis due to inhalant allergens and foods

    Mild, uncomplicated allergic skin manifestations of urticaria and angioedema

    Amelioration of allergic reactions to blood or plasma

    Cold urticaria

    Dermatographism

    As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.

  • CONTRAINDICATIONS

    Newborn or Premature Infants

    This drug should not be used in newborn or premature infants.

    Nursing Mothers

    Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.

    Other Conditions

    Hypersensitivity to cyproheptadine and other drugs of similar chemical structure

    Monoamine oxidase inhibitor therapy (see Drug Interactions)

    Angle-closure glaucoma

    Stenosing peptic ulcer

    Symptomatic prostatic hypertrophy

    Bladder neck obstruction

    Pyloroduodenal obstruction

    Elderly, debilitated patients

  • WARNINGS

    Children

    Overdosage of antihistamines, particularly in infants and children, may produce hallucinations, central nervous system depression, convulsions and death.

    Antihistamines may diminish mental alertness; conversely, particularly in the young child, they may occasionally produce excitation.

    CNS Depressants

    Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.

    Activities Requiring Mental Alertness

    Patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery.

    Antihistamines are more likely to cause dizziness, sedation and hypotension in elderly patients.

  • PRECAUTIONS

    General

    Cyproheptadine has an atropine-like action and, therefore, should be used with caution in patients with:

    History of bronchial asthma

    Increased intraocular pressure

    Hyperthyroidism

    Cardiovascular disease

    Hypertension

    Information for Patients

    Antihistamines may diminish mental alertness; conversely, particularly in the young child, they may occasionally produce excitation.

    Patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery.

    Drug Interactions

    MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.

    Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, anti-anxiety agents.

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    Long-term carcinogenic studies have not been done with cyproheptadine.

    Cyproheptadine had no effect on fertility in a two-litter study in rats or a two generation study in mice at about 10 times the human dose.

    Cyproheptadine did not produce chromosome damage in human lymphocytes or fibroblasts in vitro; high doses (10-4M) were cytotoxic. Cyproheptadine did not have any mutagenic effect in the Ames microbial mutagen test; concentrations of above 500 mcg/plate inhibited bacterial growth.

    Pregnancy

    Pregnancy Category B

    Reproduction studies have been performed in rabbits, mice and rats at oral or subcutaneous doses up to 32 times the maximum recommended human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to cyproheptadine. Cyproheptadine has been shown to be fetotoxic in rats when given by intraperitoneal injection in doses four times the maximum recommended human oral dose. Two studies in pregnant women, however, have not shown that cyproheptadine increases the risk of abnormalities when administered during the first, second and third trimesters of pregnancy. No teratogenic effects were observed in any of the newborns. Nevertheless, because the studies in humans cannot rule out the possibility of harm, cyproheptadine should be used during pregnancy only if clearly needed.

    Nursing Mothers

    It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from cyproheptadine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother (see CONTRAINDICATIONS).

    Pediatric Use

    Safety and effectiveness in pediatric patients below the age of two years have not been established. (see CONTRAINDICATIONS, Newborn or Premature Infants, and WARNINGS, Children).

  • ADVERSE REACTIONS

    Adverse reactions which have been reported with the use of antihistamines are as follows:

    Central Nervous System: Sedation and sleepiness (often transient), dizziness, disturbed coordination, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, paresthesias, neuritis, convulsions, euphoria, hallucinations, hysteria, faintness.

    Integumentary: Allergic manifestation of rash and edema, excessive perspiration, urticaria, photosensitivity.

    Special Senses: Acute labyrinthitis, blurred vision, diplopia, vertigo, tinnitus.

    Cardiovascular: Hypotension, palpitation, tachycardia, extrasystoles, anaphylactic shock.

    Hematologic: Hemolytic anemia, leukopenia, agranulocytosis, thrombocytopenia.

    Digestive System: Dryness of mouth, epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation, jaundice.

    Genitourinary: Urinary frequency, difficult urination, urinary retention, early menses.

    Respiratory: Dryness of nose and throat, thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness.

    Miscellaneous: Fatigue, chills, headache, increased appetite/weight gain.

  • OVERDOSAGE

    Antihistamine overdosage reactions may vary from central nervous system depression to stimulation especially in children. Also, atropine-like signs and symptoms (dry mouth; fixed, dilated pupils; flushing, etc.) as well as gastrointestinal symptoms may occur.

    If vomiting has not occurred spontaneously, the patient should be induced to vomit with syrup of ipecac.

    If the patient is unable to vomit, perform gastric lavage followed by activated charcoal. Isotonic or 1/2 isotonic saline is the lavage of choice. Precautions against aspiration must be taken especially in infants and children.

    When life threatening CNS signs and symptoms are present, intravenous physostigmine salicylate may be considered. Dosage and frequency of administration are dependent on age, clinical response and recurrence after response. (See package circulars for physostigmine products.)

    Saline cathartics, as milk of magnesia, by osmosis draw water into the bowel and, therefore, are valuable for their action in rapid dilution of bowel content.

    Stimulants should not be used.

    Vasopressors may be used to treat hypotension.

    The oral LD50 of cyproheptadine is 123 mg/kg, and 295 mg/kg in the mouse and rat, respectively.

  • DOSAGE AND ADMINISTRATION

    DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.

    Although intended primarily for administration to children, the oral solution is also used for administration to adults who cannot swallow tablets.

    Children

    The total daily dosage for children may be calculated on the basis of body weight or body area using approximately 0.25 mg/kg/day (0.11 mg/lb/day) or 8 mg per square meter of body surface (8 mg/m2).

    Age 2 to 6 years

    The usual dose is 2 mg (one teaspoonful) two or three times a day, adjusted as necessary to the size and response of the patient. The dose is not to exceed 12 mg a day.

    Age 7 to 14 years

    The usual dose is 4 mg (two teaspoonfuls) two or three times a day, adjusted as necessary to the size and response of the patient. The dose is not to exceed 16 mg a day.

    Adults

    The total daily dose for adults should not exceed 0.5 mg/kg/day (0.23 mg/lb/day). The therapeutic range is 4 to 20 mg a day, with the majority of patients requiring 12 to 16 mg a day. An occasional patient may require as much as 32 mg a day for adequate relief. It is suggested that dosage be initiated with 4 mg (two teaspoonfuls) three times a day and adjusted according to the size and response of the patient.

  • HOW SUPPLIED

    Cyproheptadine Hydrochloride Syrup (Cyproheptadine Hydrochloride Oral Solution, USP) (2 mg/5 mL), a pale yellow, peppermint flavored liquid, is available in the following oral dosage forms:

    NDC 0121-0788-16 – Bottles of 16 fl oz (473 mL)

    NDC 0121-4788-05 – 5 mL Unit Dose Cups, 10 cups per tray

    NDC 0121-4788-10 – 10 mL Unit Dose Cups, 10 cups per tray

    Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

    Dispense in a tight, light-resistant container as defined in the USP.

  • SPL UNCLASSIFIED SECTION

    Pharmaceutical Associates, Inc.
    Greenville, SC 29605

    www. paipharma.com

    R03/12

  • PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label

    NDC 0121-0788-16

    Cyproheptadine Hydrochloride Syrup
    (Cyproheptadine Hydrochloride Oral Solution,USP)

    2 mg/5 mL

    Each 5 mL (one teaspoonful) contains:
    Cyproheptadine hydrochloride..... 2 mg
    Alcohol 5%

    Rx ONLY

    16 fl oz (473 mL)

    pai
    Pharmaceutical
    Associates, Inc.

    Greenville, SC 29605

    PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label
  • PRINCIPAL DISPLAY PANEL - 5 mL Cup Label

    Delivers 5 mL
    NDC 0121-4788-05

    CYPROHEPTADINE HYDROCHLORIDE
    SYRUP
    (Cyproheptadine Hydrochloride Oral Solution,USP)

    2 mg/5 mL
    CONTAINS ALCOHOL 5%
    FOR INSTITUTIONAL USE ONLY

    Usual Dosage: See Package Insert for
    Complete Dosage Recommendations.

    Rx ONLY

    PHARMACEUTICAL ASSOCIATES, INC.
    GREENVILLE, SC 29605

    A47880500

    PRINCIPAL DISPLAY PANEL - 5 mL Cup Label
  • INGREDIENTS AND APPEARANCE
    CYPROHEPTADINE 
    cyproheptadine syrup
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0121-0788
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CYPROHEPTADINE (UNII: 2YHB6175DO) (CYPROHEPTADINE - UNII:2YHB6175DO) CYPROHEPTADINE2 mg  in 5 mL
    Inactive Ingredients
    Ingredient NameStrength
    ALCOHOL (UNII: 3K9958V90M)  
    CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)  
    D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  
    WATER (UNII: 059QF0KO0R)  
    SODIUM BENZOATE (UNII: OJ245FE5EU)  
    SODIUM CITRATE (UNII: 1Q73Q2JULR)  
    SUCROSE (UNII: C151H8M554)  
    Product Characteristics
    ColorYELLOW (PALE) Score    
    ShapeSize
    FlavorPEPPERMINTImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0121-0788-16473 mL in 1 BOTTLE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA09129507/29/2013
    CYPROHEPTADINE 
    cyproheptadine syrup
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0121-4788
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CYPROHEPTADINE (UNII: 2YHB6175DO) (CYPROHEPTADINE - UNII:2YHB6175DO) CYPROHEPTADINE2 mg  in 5 mL
    Inactive Ingredients
    Ingredient NameStrength
    ALCOHOL (UNII: 3K9958V90M)  
    CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)  
    D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  
    WATER (UNII: 059QF0KO0R)  
    SODIUM BENZOATE (UNII: OJ245FE5EU)  
    SODIUM CITRATE (UNII: 1Q73Q2JULR)  
    SUCROSE (UNII: C151H8M554)  
    Product Characteristics
    ColorYELLOW (PALE) Score    
    ShapeSize
    FlavorPEPPERMINTImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0121-4788-054 in 1 CASE
    110 in 1 TRAY
    15 mL in 1 CUP, UNIT-DOSE
    2NDC:0121-4788-104 in 1 CASE
    210 in 1 TRAY
    210 mL in 1 CUP, UNIT-DOSE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA09129507/29/2013
    Labeler - Pharmaceutical Associates, Inc. (044940096)
    Establishment
    NameAddressID/FEIBusiness Operations
    Pharmaceutical Associates, Inc.097630693MANUFACTURE(0121-0788, 0121-4788)